Zomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave Therapy
Zomedica (OTCQB:ZOMDF) has launched the Equine Asthma Clinical Registry, a groundbreaking program utilizing PulseVet® shock wave therapy as a non-invasive, drug-free treatment for equine asthma. The initiative aims to gather real-world clinical evidence on the effectiveness of electrohydraulic extracorporeal shock wave therapy (ESWT) in treating respiratory conditions in horses.
Initial studies show promising results, with 58 horses completing treatment without adverse events. The registry allows veterinary clinics to enroll up to 20 horses, requiring three scheduled visits over 4-6 weeks. Equine asthma affects approximately 15% of horses over age seven, impacting their performance and quality of life. The program offers participating clinics product credits while contributing to vital research in advancing equine respiratory care.
Zomedica (OTCQB:ZOMDF) ha lanciato il Registro Clinico per l'Asma Equina, un programma innovativo che utilizza la terapia a onde d'urto PulseVet® come trattamento non invasivo e senza farmaci per l'asma equina. L'iniziativa mira a raccogliere dati clinici reali sull'efficacia della terapia extracorporea a onde d'urto elettroidrauliche (ESWT) nel trattamento delle patologie respiratorie nei cavalli.
Gli studi iniziali mostrano risultati promettenti, con 58 cavalli che hanno completato il trattamento senza eventi avversi. Il registro consente alle cliniche veterinarie di iscrivere fino a 20 cavalli, con tre visite programmate nell'arco di 4-6 settimane. L'asma equina colpisce circa il 15% dei cavalli con più di sette anni, influenzandone le prestazioni e la qualità della vita. Il programma offre alle cliniche partecipanti crediti sui prodotti, contribuendo allo stesso tempo a ricerche fondamentali per il progresso della cura respiratoria equina.
Zomedica (OTCQB:ZOMDF) ha lanzado el Registro Clínico de Asma Equina, un programa innovador que utiliza la terapia con ondas de choque PulseVet® como un tratamiento no invasivo y sin medicamentos para el asma equina. La iniciativa busca recopilar evidencia clínica real sobre la efectividad de la terapia extracorpórea con ondas de choque electrohidráulicas (ESWT) en el tratamiento de enfermedades respiratorias en caballos.
Los estudios iniciales muestran resultados prometedores, con 58 caballos que completaron el tratamiento sin eventos adversos. El registro permite a las clínicas veterinarias inscribir hasta 20 caballos, con tres visitas programadas en un periodo de 4-6 semanas. El asma equina afecta aproximadamente al 15% de los caballos mayores de siete años, impactando su rendimiento y calidad de vida. El programa ofrece créditos en productos a las clínicas participantes, a la vez que contribuye a investigaciones vitales para avanzar en el cuidado respiratorio equino.
Zomedica (OTCQB:ZOMDF)는 비침습적이며 약물 없는 말 천식 치료법으로 PulseVet® 충격파 치료를 활용하는 획기적인 프로그램인 말 천식 임상 등록부를 시작했습니다. 이 이니셔티브는 말의 호흡기 질환 치료에 있어 전기유압 체외 충격파 치료(ESWT)의 효과에 대한 실제 임상 증거를 수집하는 것을 목표로 합니다.
초기 연구 결과는 58마리의 말이 부작용 없이 치료를 완료하는 등 유망한 결과를 보여줍니다. 이 등록부는 수의과 클리닉이 최대 20마리의 말을 등록할 수 있도록 하며, 4-6주 동안 세 번의 예정된 방문이 필요합니다. 말 천식은 7세 이상의 말 중 약 15%에 영향을 미치며, 말의 수행 능력과 삶의 질에 영향을 줍니다. 이 프로그램은 참여 클리닉에 제품 크레딧을 제공하며, 말 호흡기 치료 발전에 중요한 연구에 기여합니다.
Zomedica (OTCQB:ZOMDF) a lancé le Registre Clinique de l'Asthme Équin, un programme innovant utilisant la thérapie par ondes de choc PulseVet® comme traitement non invasif et sans médicaments pour l'asthme équin. Cette initiative vise à recueillir des preuves cliniques réelles sur l'efficacité de la thérapie extracorporelle par ondes de choc électrohydrauliques (ESWT) dans le traitement des affections respiratoires chez les chevaux.
Les premières études montrent des résultats prometteurs, avec 58 chevaux ayant terminé le traitement sans événements indésirables. Le registre permet aux cliniques vétérinaires d'inscrire jusqu'à 20 chevaux, avec trois visites programmées sur 4 à 6 semaines. L'asthme équin touche environ 15 % des chevaux de plus de sept ans, affectant leurs performances et leur qualité de vie. Le programme offre aux cliniques participantes des crédits produits tout en contribuant à la recherche essentielle pour faire progresser les soins respiratoires équins.
Zomedica (OTCQB:ZOMDF) hat das Equine Asthma Clinical Registry gestartet, ein bahnbrechendes Programm, das die PulseVet® Stoßwellentherapie als nicht-invasive, medikamentenfreie Behandlung für Pferdeasthma einsetzt. Die Initiative zielt darauf ab, klinische Realwelt-Daten zur Wirksamkeit der elektrohydraulischen extrakorporalen Stoßwellentherapie (ESWT) bei der Behandlung von Atemwegserkrankungen bei Pferden zu sammeln.
Erste Studien zeigen vielversprechende Ergebnisse, wobei 58 Pferde die Behandlung ohne unerwünschte Ereignisse abgeschlossen haben. Das Register ermöglicht es Tierkliniken, bis zu 20 Pferde anzumelden, mit drei geplanten Besuchen über 4-6 Wochen. Pferdeasthma betrifft etwa 15 % der Pferde über sieben Jahre und beeinträchtigt deren Leistung und Lebensqualität. Das Programm bietet teilnehmenden Kliniken Produktgutschriften und trägt gleichzeitig zu wichtiger Forschung zur Weiterentwicklung der Atemwegspflege bei Pferden bei.
- Development of innovative non-drug treatment alternative for equine asthma
- Successful treatment of 58 horses with no reported adverse events
- Program includes incentives for veterinary clinics through product credits
- Targets a significant market with 15% of horses over age seven affected by asthma
- Treatment requires multiple clinic visits over 4-6 weeks
- Limited data available on long-term effectiveness
Insights
Zomedica's launch of an Equine Asthma Clinical Registry using its PulseVet therapy represents a strategic move to build clinical evidence supporting a non-drug treatment option.
Zomedica's new Equine Asthma Clinical Registry represents a significant development in the company's strategy to expand clinical applications for its PulseVet shock wave therapy system. This initiative targets equine asthma, which affects approximately
The registry serves multiple strategic purposes: it generates real-world clinical evidence for a novel application of shock wave therapy, creates veterinary engagement through participation incentives (product credits for enrolling up to 20 horses), and positions Zomedica's technology as a non-pharmacological alternative in respiratory care. The preliminary data cited (58 horses treated with no adverse events) suggests safety, while Dr. Whitaker's observations indicate potential efficacy in reducing respiratory symptoms.
From a product development perspective, this registry demonstrates Zomedica's commitment to evidence-based medicine – a growing priority in veterinary care. By systematically collecting outcomes data through the required three visits over 4-6 weeks, the company builds a foundation for potential peer-reviewed publications, conference presentations, and marketing claims that could differentiate PulseVet in a competitive market.
The equine respiratory market represents an expansion opportunity beyond PulseVet's established applications. By approaching equine asthma – a condition typically managed with medications – Zomedica is potentially opening a new revenue stream while positioning itself as an innovator in the veterinary medical device sector.
Innovative Registry Harnesses Shock Wave Therapy to Advance Non-Drug Equine Asthma Treatment and Drive Evidence-Based Veterinary Care
ANN ARBOR, MI / ACCESS Newswire / May 13, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of the Equine Asthma Clinical Registry. This pioneering program leverages PulseVet® shock wave therapy to offer a non-invasive, drug-free treatment alternative for horses suffering from asthma.
Equine asthma is a common yet often underdiagnosed condition, affecting an estimated
Recent clinical studies have demonstrated that electrohydraulic extracorporeal shock wave therapy (ESWT) using the PulseVet device can significantly improve clinical signs in horses diagnosed with respiratory conditions. To date, 58 horses have completed treatment for respiratory conditions, with no reported adverse events.
Dr. Beau Whitaker, DVM, of Brazos Valley Equine Hospital, commented, "We've observed measurable reductions in respiratory effort, cough frequency, and overall clinical signs following ESWT treatment. It's a promising adjunct therapy for managing equine asthma."
Veterinary clinics can enroll up to 20 horses, contributing to vital research while receiving product credits. Participants are required to complete three scheduled visits per horse over a 4-6 week period, with assessments conducted at each visit.
"The launch of this clinical registry marks an important milestone in our commitment to advancing patient care. By systematically collecting real-world data for the treatment of equine asthma, we aim to generate critical insights that will inform clinical practice, guide future research, and ultimately improve outcomes for patients. This initiative reflects our ongoing dedication to evidence-based innovation and collaboration," said Ashley Wood PhD, Zomedica's Vice President of Research and Development.
Courtney Calnan, Senior Product Manager at Zomedica, added: "What makes this registry so exciting is that it bridges cutting-edge science with everyday clinical application. We're providing veterinarians with tools and data that empower them to deliver better outcomes for their patients-without relying solely on medications. It's a true step forward in equine respiratory care."
This initiative not only offers a novel treatment avenue for equine asthma but also reinforces Zomedica's commitment to advancing animal healthcare through innovative, evidence-based solutions.
For more information or to enroll in the Equine Asthma Clinical Registry, please visit: https://pulsevet.zomedica.com/shock-wave-therapy/equine-asthma-clinical-registry/
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes;; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
What is Zomedica's new Equine Asthma Clinical Registry program?
How many horses have been treated with ZOM's PulseVet therapy for respiratory conditions?
What percentage of horses are affected by equine asthma according to Zomedica?
How can veterinary clinics participate in Zomedica's Equine Asthma Registry?
What are the benefits of ZOM's PulseVet shock wave therapy for horses?
